Ibrutinib and other Bruton Tyrosine Kinase (BTK) inhibitors have transformed the treatment landscape for chronic lymphocytic leukemia (CLL) by targeting B-cell receptor (BCR) signaling, a central component in CLL cell survival and proliferation. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.